Hyperbilirubinemia in the setting of antiviral therapy

Clinical Gastroenterology and Hepatology

Volumn 3, Issue 4, 2005, Pages 303-310

  Korenblat, Kevin M ^a,c   Berk, Paul D ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; AMPRENAVIR; ANTIVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENZYME INHIBITOR; ERYTHROPOIETIN; GANCICLOVIR; GLUCURONOSYLTRANSFERASE 1A1; GUANIDINE DERIVATIVE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIMICROBIAL THERAPY; BILIRUBIN BINDING; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; GENETIC RISK; GENETIC SUSCEPTIBILITY; GILBERT DISEASE; GLUCURONIDATION; HEMOLYSIS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; INFECTION PREVENTION; LACTIC ACIDOSIS; LEUKOCYTOSIS; LIVER CELL DAMAGE; LIVER CLEARANCE; LIVER FAILURE; LIVER LEVEL; LIVER METABOLISM; LIVER MITOCHONDRION; LIVER TOXICITY; MIXED HYPERBILIRUBINEMIA; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; SEX RATIO; SIDE EFFECT; STEATOSIS; UNCONJUGATED HYPERBILIRUBINEMIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; HYPERBILIRUBINEMIA; INCIDENCE; LIVER FUNCTION TESTS; MALE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VIRUS DISEASES;

EID: 16844383493     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(05)00083-2     Document Type: Review

References (40)

1. N. Roy Chowdhury, I.M. Arias, A.W. Wolkoff Disorders of bilirubin metabolism I.M. Arias J.L. Boyer F.V. Chisari The liver biology and pathobiology 4th ed. 2001 Lippincott Williams & Wilkins Philadelphia 291 309
2. P. Berk, R. Howe, J. Bloomer Studies of bilirubin kinetics in normal adults J Clin Invest 48 1969 2176 2190
3. P.D. Berk, A.W. Wolkoff Bilirubin metabolism and the hyperbilirubinemias E. Braunwald A.S. Fauci D.L. Kasper Harrison's principles of internal medicine 15th ed. 2001 McGraw-Hill New York 1715 1720
4. S. Zucker, W. Goessling, A. Hoppin Unconjugated bilirubin exhibits spontaneous diffusion through model lipid bilayers and native hepatocyte membranes J Biol Chem 274 1999 10852 10862
5. J.K. Ritter, F. Chen, Y.Y. Sheen A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini J Biol Chem 267 1992 3257 3261
6. P.J. Bosma, J. Seppen, B. Goldhoorn Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man J Biol Chem 269 1994 17960 17964
7. Z.C. Gatmaitan, I.M. Arias ATP-dependent transport systems in the canalicular membrane of the hepatocyte Physiol Rev 75 1995 261 275
8. S. Kikuchi, M. Hata, K. Fukumoto Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes Nat Genet 31 2002 320 325
9. J. Kartenbeck, U. Leuschner, R. Mayer Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome Hepatology 23 1996 1061 1066
10. P.D. Berk, J.F. Martin, T.F. Blaschke Unconjugated hyperbilirubinemia physiologic evaluation and experimental approaches to therapy Ann Intern Med 82 1975 552 570
11. P.D. Berk Approach to the patient with jaundice or abnormal liver tests L. Goldman D.W. Powell J.M. Drazen Cecil's textbook of medicine 22nd ed. 2004 WB Saunders Philadelphia 897 906
12. K.J. Robertson, D. Clarke, L. Sutherland Investigation of the molecular basis of the genetic deficiency of UDP-glucuronosyl-transferase in Crigler-Najjar syndrome J Inherit Metab Dis 14 1991 563 579
13. P.D. Berk, J.R. Bloomer, R.B. Howe Constitutional hepatic dysfunction (Gilbert's syndrome) a new definition based on kinetic studies with unconjugated radiobilirubin Am J Med 49 1970 296 305
14. B. Burchell, R. Hume Molecular genetic basis of Gilbert's syndrome J Gastroenterol Hepatol 14 1999 960 966
15. R. Thompson, P.L. Jansen Genetic defects in hepatocanalicular transport Semin Liver Dis 20 2000 365 372
16. M.A. Poles, D.T. Dieterich Infections of the liver in HIV-infected patients Infect Dis Clin North Am 14 2000 741 759
17. D.R. Dufour Evaluation of liver function and injury J.B. Henry Clinical diagnosis and management by laboratory methods 20th ed. 2001 WB Saunders Philadelphia 264 280
18. M.S. Sulkowski, D.L. Thomas, R.E. Chaisson Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection JAMA 283 2000 74 80
19. D.T. Dieterich Human immunodeficiency virus and the liver lessons learned and still to be learned Semin Liver Dis 23 2003 107 114
20. AIDS Clinical Trials Group Table of grading severity of adult adverse experiences 1996 National Institute of Allergy and Infectious Diseases, Division of AIDS Rockville, MD
21. V. Montessori, M. Harris, J.S. Montaner Hepatotoxicity of nucleoside reverse transcriptase inhibitors Semin Liver Dis 23 2003 167 172
22. W. Lewis, M.C. Dalakas Mitochondrial toxicity of antiviral drugs Nat Med 1 1995 417 422
23. A.M. Martin, E. Hammond, D. Nolan Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors Am J Hum Genet 72 2003 549 560
24. K.K. Lai, D.L. Gang, J.K. Zawacki Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI) Ann Intern Med 115 1991 283 284
25. Y. Bourezane, D. Salard, B. Hoen DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy Clin Infect Dis 27 1998 1321 1322
26. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997-2000 MMWR Morb Mortal Wkly Rep 49 2001 1153 1156
27. M.S. Sulkowski, D.L. Thomas, S.H. Mehta Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy role of hepatitis C and B infections Hepatology 35 2002 182 189
28. R. Palmon, B.C. Koo, D.A. Shoultz Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors J Acquir Immune Defic Syndr 29 2002 340 345
29. N. Kontorinis, D.T. Dieterich Toxicity of non-nucleoside analogue reverse transcriptase inhibitors Semin Liver Dis 23 2003 173 182
30. G.L. Plosker, S. Noble Indinavir a review of its use in the management of HIV infection Drugs 58 1999 1165 1203
31. M.S. Sulkowski Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors Semin Liver Dis 23 2003 183 194
32. C.R. Rayner, L.D. Esch, H.E. Wynn Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen Ann Pharmacother 35 2001 1391 1395
33. S.D. Zucker, X. Qin, S.D. Rouster Mechanism of indinavir-induced hyperbilirubinemia Proc Natl Acad Sci U S A 98 2001 12671 12676
34. I. Sanne, P. Piliero, K. Squires Results of a phase 2 clinical trial at 48 weeks (AI424-007) a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects J Acquir Immune Defic Syndr 32 2003 18 29
35. D.W. Haas, C. Zala, S. Schrader Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy a randomized comparative pilot trial AIDS 17 2003 1339 1349
36. R.J. Whitley, G. Cloud, W. Gruber Ganciclovir treatment of symptomatic congenital cytomegalovirus infection results of a phase II study--National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group J Infect Dis 175 1997 1080 1086
37. B. Salzberger, R.A. Bowden, R.C. Hackman Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease risk factors and outcome Blood 90 1997 2502 2508
38. J.G. McHutchison, S.C. Gordon, E.R. Schiff Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1485 1492
39. G.L. Davis, R. Esteban-Mur, V. Rustgi Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C International Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1493 1499
40. D.T. Dieterich Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients J Infect Dis 185 Suppl 2 2002 S128 S137